CA3171185A1 - Macrocyclic ulk1/2 inhibitors - Google Patents

Macrocyclic ulk1/2 inhibitors

Info

Publication number
CA3171185A1
CA3171185A1 CA3171185A CA3171185A CA3171185A1 CA 3171185 A1 CA3171185 A1 CA 3171185A1 CA 3171185 A CA3171185 A CA 3171185A CA 3171185 A CA3171185 A CA 3171185A CA 3171185 A1 CA3171185 A1 CA 3171185A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
cycloalkyl
heterocycloalkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171185A
Other languages
English (en)
French (fr)
Inventor
Nicholas D.P. Cosford
Nicole A. Bakas
Reuben J. Shaw
Allison S. LIMPERT
Sonja N. BRUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Salk Institute for Biological Studies
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute, Salk Institute for Biological Studies filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of CA3171185A1 publication Critical patent/CA3171185A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3171185A 2020-02-14 2021-02-12 Macrocyclic ulk1/2 inhibitors Pending CA3171185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977039P 2020-02-14 2020-02-14
US62/977,039 2020-02-14
PCT/US2021/018038 WO2021163627A1 (en) 2020-02-14 2021-02-12 Macrocyclic ulk1/2 inhibitors

Publications (1)

Publication Number Publication Date
CA3171185A1 true CA3171185A1 (en) 2021-08-19

Family

ID=77292762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171185A Pending CA3171185A1 (en) 2020-02-14 2021-02-12 Macrocyclic ulk1/2 inhibitors

Country Status (8)

Country Link
US (1) US12594277B2 (https=)
EP (1) EP4103183A4 (https=)
JP (1) JP2023513793A (https=)
KR (1) KR20220153582A (https=)
CN (1) CN115515588A (https=)
AU (1) AU2021221162A1 (https=)
CA (1) CA3171185A1 (https=)
WO (1) WO2021163627A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216440A1 (en) * 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2022072668A1 (en) * 2020-09-30 2022-04-07 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors
TW202404979A (zh) * 2022-07-18 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抑制並誘導ｅｇｆｒ降解的大環類化合物、其製備方法及其在醫藥上的應用
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2024233766A1 (en) * 2023-05-10 2024-11-14 Erasca, Inc. Macrocyclic ulk1/2 inhibitors and their use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
MXPA06013165A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2006037117A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2007028445A1 (en) 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
EP2089369B1 (en) 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
BRPI0810641A2 (pt) 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
WO2008140421A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Heterocycloalkyl substituted pyrimidine derivatives
JP2011505407A (ja) 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
WO2009083185A2 (en) 2007-12-28 2009-07-09 Fovea Pharmaceuticals Sa Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EA201100078A1 (ru) 2008-06-25 2011-08-30 Айрм Ллк Производные пиримидина в качестве ингибиторов киназы
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PL2310492T3 (pl) * 2008-06-30 2015-12-31 Janssen Biotech Inc Różnocowanie pluripotencjalnych komórek macierzystych
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
US20120165332A1 (en) 2009-06-18 2012-06-28 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US20130040310A1 (en) 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
WO2011084108A1 (en) 2010-01-08 2011-07-14 Agency For Science, Technology And Research Methods and compositions for treating cancer
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
WO2012040602A2 (en) 2010-09-23 2012-03-29 President And Fellows Of Harvard College Targeting mtor substrates in treating proliferative diseases
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
JP2014511391A (ja) 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
EP2780017A1 (en) 2011-11-15 2014-09-24 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
ES2552518T3 (es) 2012-02-21 2015-11-30 Merck Patent Gmbh Derivados cíclicos de diaminopiridina como inhibidores de Syk
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014098932A1 (en) 2012-12-17 2014-06-26 The Brigham And Women's Hosptial, Inc. Treatment of mtor hyperactive related diseases and disorders
CN103059030B (zh) 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
CA2899281C (en) 2013-01-25 2022-05-31 Rigel Pharmaceuticals, Inc. Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
WO2014197680A1 (en) 2013-06-05 2014-12-11 Salk Institute For Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
US10300058B2 (en) 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
CA2952787A1 (en) 2014-06-17 2015-12-23 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
DK3185868T3 (da) * 2014-08-25 2022-05-23 Salk Inst For Biological Studi Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
CN105524045B (zh) 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
WO2016090079A1 (en) 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106188029B (zh) 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105801603B (zh) 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
EP3528814B1 (en) 2016-10-18 2024-08-14 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
JP6684700B2 (ja) 2016-12-26 2020-04-22 アイシン精機株式会社 乗員検知装置
EP3620457A4 (en) 2017-05-02 2021-01-06 Korea Research Institute of Chemical Technology PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
IL325201A (en) 2019-06-17 2026-02-01 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of using them
CN115515589A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 Ulk1/2抑制剂及其使用方法
JP2023513797A (ja) 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２阻害剤による単剤療法および併用療法
WO2021216440A1 (en) 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2022072668A1 (en) 2020-09-30 2022-04-07 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors

Also Published As

Publication number Publication date
EP4103183A4 (en) 2024-02-28
WO2021163627A1 (en) 2021-08-19
JP2023513793A (ja) 2023-04-03
US12594277B2 (en) 2026-04-07
CN115515588A (zh) 2022-12-23
KR20220153582A (ko) 2022-11-18
EP4103183A1 (en) 2022-12-21
US20230099804A1 (en) 2023-03-30
AU2021221162A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CA3171185A1 (en) Macrocyclic ulk1/2 inhibitors
CN114929704A (zh) 含螺环的喹唑啉化合物
AU2015266453C1 (en) Alk kinase inhibitor, and preparation method and use thereof
AU2016312011A1 (en) Process for preparing Parp inhibitor, crystalline forms, and uses thereof
WO2021163629A1 (en) Inhibitors of ulk1/2 and methods of using same
CN105517549B (zh) CaMKII抑制剂和其用途
CA3116931A1 (en) Heterocyclic compounds as bet inhibitors
AU2014230125A1 (en) Macrocyclic salt-inducible kinase inhibitors
RU2691401C2 (ru) Подготовка и использование ингибитора киназы
AU2011221849A1 (en) Pyrazolopyrimidine derivative
JPWO2020032105A1 (ja) 光学活性な架橋型ピペリジン誘導体
EP3496724B1 (en) Protein kinase regulators
EP3452465A1 (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
BR112018072039B1 (pt) Composto, medicamento, e, uso do composto ou sal do mesmo
KR20200014350A (ko) 단백질 키나아제 억제제로서의 아미노티아졸 화합물
AU2009284086B2 (en) New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents
JP2021134218A (ja) 光学活性なアザビシクロ環誘導体からなる医薬
AU2020270908B2 (en) Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use
KR20240041340A (ko) 피롤로피리미딘 유도체 화합물 및 이의 용도
WO2022248682A1 (en) Compounds for degradation of cyclin-dependent kinase 7 (cdk7)
RU2851633C1 (ru) Соединения хиназолина, содержащие спиро-кольцо
CN116693515A (zh) 一种gst蛋白抑制剂、其制备方法、药用组合物及其用途
HK40078982B (en) Trka inhibitor
EA051813B1 (ru) Пиразолопиримидиновое соединение, его фармацевтическая композиция, способ лечения и применение
CN111978318A (zh) 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240823

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250605

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260326